COTC026: Evaluation of a Recombinant, Attenuated Listeria monocytogenes Expressing a Chimeric Human HER2 / neu Protein
in Dogs with Osteosarcoma in the Adjuvant Setting T Fan; $ 585,144; Morris Animal Foundation
Starting this spring, we will be participating in a study to evaluate the Canine Osteosarcoma Vaccine, Live Listeria Vector (COV - LLV), a conditionally licensed product
for dogs with osteosarcoma who have undergone amputation and chemotherapy.
The treatment of choice by veterinarians for
most dogs with osteosarcoma of the leg is amputation of the affected limb, after which most dogs do function quite well.
Sivacolundhu et al recently published a study (JAVMA July 2013) in which they compared survival times in
dogs with osteosarcoma of the ulna undergoing amputation compared to those who under went a limb sparing surgery known as a partial ulnectomy, in which the lower part of the ulna is removed.
This is a study sponsored by the Canine Health Foundation and supported by the IWF to evaluate treatments which may delay the onset of metastatic disease in
dogs with osteosarcoma who have undergone amputation and chemotherapy.
Leeper and collaborators at OSU and Iowa State University compared 64
dogs with osteosarcoma against two control groups: 30 dogs that had suffered traumatic bone fractures and 31 healthy dogs similar in age and weight to the animals with cancer.
Researchers will enroll 80 client -
owned dogs with osteosarcoma that will receive current standard - of - care therapy, which includes surgical removal of the tumor and chemotherapy.
The purpose of this study was to determine if adding the oral drug Rapamycin into the treatment protocol
for dogs with osteosarcoma will be safe and improve efficacy of current standard therapies for osteosarcoma in dogs.
«Scientists test nanoparticle drug delivery in
dogs with osteosarcoma.»
Dogs with osteosarcoma that has spread to the lungs may also have difficulty breathing or exercise intolerance.
Purpose of Study: This clinical trial evaluated the safety and effectiveness of rapamycin when given to
dogs with osteosarcoma or soft tissue sarcomas.
Dr. Nicola Mason, recent IWF - sponsored speaker at GLIWA and IWADV, has launched an exciting new study for
dogs with osteosarcoma.
Young
dogs with osteosarcoma tend to have shorter survival times and more aggressive disease than older dogs with osteosarcoma.
Because of this high incidence of metastasis,
all dogs with osteosarcoma are treated as though they have metastasis to the lungs regardless of the findings on the initial lung x-rays.
«In order to be eligible for the study,
a dog with osteosarcoma must have the primary tumor removed and undergo chemotherapy.»
Serum levels of VEGF are increased in
dogs with osteosarcoma, malignant melanoma and HSA and in dogs with osteosarcoma and malignant melanoma, serum levels correlate with disease free interval and survival times respectively.
Palliative surgery is frequently performed in
dogs with osteosarcoma (bone cancer) by amputating a limb, or a spleen removed in dogs with hemangiosarcoma in order to prevent internal bleeding.
Most
dogs with osteosarcoma that undergo amputation and chemotherapy, just like «Layla,» only live for about a year.
The combination of amputation and chemotherapy provides the best outlook for
dogs with osteosarcoma, with half of the patients surviving for one year and a quarter of them surviving for two years.
Only 10 percent of
dogs with osteosarcoma will have observable evidence of cancer spread, but the remaining 90 - percent likely already will have microscopic metastases.